# Multi‐Omics Revealed the Effects of Intrauterine Hyperglycemia Exposure on the Development of Skeletal Muscle in Offspring

**Authors:** Rui Liu, Junsen She, Xinyuan Li, Yishang Yan, Jiaying Mo, Jianzhong Sheng, Hongbo Yang, Hefeng Huang

PMC · DOI: 10.1002/jcsm.70177 · 2026-01-22

## TL;DR

Exposure to high blood sugar in the womb harms offspring's muscle development, but exercise after birth can help reverse some of these effects.

## Contribution

This study reveals how intrauterine hyperglycemia affects skeletal muscle development and shows that postnatal exercise can mitigate some of these effects.

## Key findings

- IUHG leads to increased body weight, impaired glucose and insulin tolerance, and reduced muscle strength in offspring.
- Postnatal exercise improves muscle structure, lipid profiles, and metabolic function in GDM-exposed offspring.
- Transcriptomic and epigenomic changes in skeletal muscle include altered immune regulation, myogenesis, and lipid metabolism.

## Abstract

Gestational diabetes mellitus (GDM), a common pregnancy complication characterized by maternal hyperglycemia, negatively impacts offspring health. Skeletal muscle, a critical tissue for glucose and lipid metabolism, is especially vulnerable to prenatal environmental insults. However, the effects of intrauterine hyperglycemia (IUHG) on offspring skeletal muscle development remain poorly understood. This study aimed to investigate the effects of IUHG on skeletal muscle development in offspring and evaluate whether postnatal exercise could mitigate these effects.

Pregnant mice were assigned to GDM and control groups. Offspring were further divided into control and exercise subgroups. Body weight, glucose tolerance test (GTT), insulin tolerance test (ITT), body composition, muscle strength and exercise capacity were assessed. At 20 weeks of age, skeletal muscle morphology was evaluated via various staining and Transmission Electron Microscope. Transcriptomic changes were analysed by RNA sequencing (RNA‐seq) and chromatin accessibility was assessed using ATAC‐seq to identify molecular mechanisms underlying IUHG‐induced alterations. Additionally, primary fetal myoblasts were cultured under normal and high‐glucose conditions to investigate metabolic changes and lipid accumulation in vitro.

Offspring exposed to IUHG exhibited increased body weight, impaired glucose and insulin tolerance, altered body composition, reduced muscle strength and diminished exercise capacity at adulthood. Exercise intervention in diabetic offspring improved the muscle ratio (p < 0.05), fat ratio (p < 0.05), lipid profiles (p < 0.005) and muscle structure and strength (p < 0.005). Transcriptomic and epigenomic profiling identified significant changes in genes and regulatory elements associated with immune regulation, myogenesis, lipid metabolism and inflammation in GDM‐exposed offspring. In vitro, high‐glucose exposure of E14.5d fetal myoblasts led to significant metabolic reprogramming, including lipid accumulation and disruptions in glycolysis and oxidative metabolism. Furthermore, the expression of AP‐1 family members Fos and Junb was up‐regulated in myoblasts under high‐glucose conditions, which aligns with the findings in the in vivo models.

IUHG disrupts skeletal muscle development and metabolic function in offspring through structural, transcriptional and epigenetic alterations. Postnatal exercise partially reversed these impairments, highlighting its potential as a non‐pharmacological intervention. These findings provide new insights into the developmental origins of skeletal muscle dysfunction in GDM‐exposed offspring and underscore the importance of early prevention strategies.

## Linked entities

- **Genes:** FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353], JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726]
- **Diseases:** gestational diabetes mellitus (MONDO:0005406)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, Junb (jun B proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16477], Ccl6 (C-C motif chemokine ligand 6) [NCBI Gene 20305] {aka MRP-1, Scya6, c10}, Ccl3 (C-C motif chemokine ligand 3) [NCBI Gene 20302] {aka G0S19-1, LD78alpha, MIP-1alpha, MIP1-(a), MIP1-alpha, Mip1a}, Atf7 (activating transcription factor 7) [NCBI Gene 223922] {aka 1110012F10Rik, 9430065F09Rik, C130020M04Rik}, ATF3 (activating transcription factor 3) [NCBI Gene 467], Ccl12 (C-C motif chemokine ligand 12) [NCBI Gene 20293] {aka MCP-5, Scya12}, JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3726] {aka AP-1}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Batf (basic leucine zipper transcription factor, ATF-like) [NCBI Gene 53314] {aka B-ATF, SFA-2}, Cxcl5 (C-X-C motif chemokine ligand 5) [NCBI Gene 20311] {aka AMCF-II, Cxcl6, ENA-78, GCP-2, LIX, Scyb5}, Cxcr6 (C-X-C motif chemokine receptor 6) [NCBI Gene 80901] {aka BONZO, STRL33}, Tlr8 (toll-like receptor 8) [NCBI Gene 170744], Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, Cd28 (CD28 antigen) [NCBI Gene 12487], Cxcl3 (C-X-C motif chemokine ligand 3) [NCBI Gene 330122] {aka Dcip1, Gm1960}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Ccl20 (C-C motif chemokine ligand 20) [NCBI Gene 20297] {aka CKb4, LARC, MIP-3A, MIP-3[a], MIP3A, ST38}, Slc15a4 (solute carrier family 15, member 4) [NCBI Gene 100561] {aka C130069N12Rik, PHT1, PTR4}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, Trem1 (triggering receptor expressed on myeloid cells 1) [NCBI Gene 58217], Gp6 (glycoprotein 6 platelet) [NCBI Gene 243816] {aka 9830166G18Rik, Gm469, Gpvi}, Ccl4 (C-C motif chemokine ligand 4) [NCBI Gene 20303] {aka AT744.1, Act-2, MIP-1B, Mip1b, Scya4}, Il1a (interleukin 1 alpha) [NCBI Gene 16175] {aka Il-1a}, Erbb2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 13866] {aka Erbb-2, HER-2, HER2, Neu, c-erbB2, c-neu}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, Bach2 (BTB and CNC homology, basic leucine zipper transcription factor 2) [NCBI Gene 12014] {aka E030004N02Rik}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, Ptk2 (PTK2 protein tyrosine kinase 2) [NCBI Gene 14083] {aka FADK 1, FAK, FRNK, Fadk, p125FAK}, Fosl1 (fos-like antigen 1) [NCBI Gene 14283] {aka Fra1, fra-1}, Il33 (interleukin 33) [NCBI Gene 77125] {aka 9230117N10Rik, Il-33, Il1f11, NF-HEV}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}, Creb1 (cAMP responsive element binding protein 1) [NCBI Gene 12912] {aka 2310001E10Rik, 3526402H21Rik, Creb, Creb-1}, Itgb7 (integrin beta 7) [NCBI Gene 16421] {aka Ly69}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, S100a1 (S100 calcium binding protein A1) [NCBI Gene 20193] {aka S100, S100a}, Il15ra (interleukin 15 receptor, alpha chain) [NCBI Gene 16169] {aka IL-15RA}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Tlr1 (toll-like receptor 1) [NCBI Gene 21897], Samd11 (sterile alpha motif domain containing 11) [NCBI Gene 231004] {aka mr-s}, Tlr13 (toll-like receptor 13) [NCBI Gene 279572] {aka Gm713}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tlr3 (toll-like receptor 3) [NCBI Gene 142980], Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 14281] {aka D12Rfj1, c-fos, cFos}, Ly86 (lymphocyte antigen 86) [NCBI Gene 17084] {aka MD-1, MD1, ly86_tv2}, Foxm1 (forkhead box M1) [NCBI Gene 14235] {aka Fkh16, Foxm1b, HFH-11B, MPHOSPH2, Mpm2, WIN}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Atf3 (activating transcription factor 3) [NCBI Gene 11910] {aka LRG-21}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Fosl2 (fos-like antigen 2) [NCBI Gene 14284] {aka Fra-2}, Ccl9 (C-C motif chemokine ligand 9) [NCBI Gene 20308] {aka CCF18, MRP-2, Scya10, Scya9}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}
- **Diseases:** Hyperglycemia (MESH:D006943), hypertension (MESH:D006973), obesity (MESH:D009765), mitochondrial dysfunction (MESH:D028361), macrosomia (MESH:D005320), ectopic (MESH:C566852), atrophy (MESH:D001284), fetal growth restriction (MESH:D005317), Maternal obesity (MESH:D000079262), muscle atrophy (MESH:D009133), muscle dysfunction (MESH:D009135), skeletal muscle (MESH:D005207), acidosis (MESH:D000138), sepsis (MESH:D018805), malignancy (MESH:D009369), maternal malnutrition (MESH:D044342), abnormal skeletal muscle phenotype (MESH:D009139), complication (MESH:D008107), immune (MESH:D007154), abnormalities (MESH:D000014), diabetes (MESH:D003920), Type 1 diabetes (MESH:D003922), glucose tolerance (MESH:D018149), Exercise (MESH:D000092202), in muscle strength (MESH:D019042), GDM (MESH:D016640), insulin deficiency (MESH:D007333), depression (MESH:D003866), atherosclerosis (MESH:D050197), hyperglycemic (MESH:D006944), metabolic diseases (MESH:D008659), chronic inflammation (MESH:D007249), weight gain (MESH:D015430), starvation (MESH:D013217), ectopic fat (MESH:D004620), abnormal glucose and lipid metabolism (MESH:D052439), abnormal maternal glucose metabolism (MESH:D044882)
- **Chemicals:** Glucose (MESH:D005947), myo-Inositol (MESH:D007294), 4-Pyridoxic acid (MESH:D011735), fatty acid (MESH:D005227), Glutamate (MESH:D018698), calcium (MESH:D002118), Lipid (MESH:D008055), citrate (MESH:D019343), Glucose 6-phosphate (MESH:D019298), Lactate (MESH:D019344), NEFA (MESH:D005230), Chemicals and Reagents (-), Nile Red (MESH:C044808), beta-Alanine (MESH:D015091), HE (MESH:D006371), Pyroglutamic acid (MESH:D011761), STZ (MESH:D013311), Nitrilotriacetic acid (MESH:D009571), water (MESH:D014867), LPS (MESH:D008070), Pinolenic acid (MESH:C034302), Palmitic acid (MESH:D019308), Pantothenic acid (MESH:D010205), TG (MESH:D014280), Oil Red O (MESH:C011049), cholesterol (MESH:D002784), Blood glucose (MESH:D001786), MDB (MESH:C000608249)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12827489/full.md

---
Source: https://tomesphere.com/paper/PMC12827489